The therapeutic approach of patients with metastatic renal cell carcinoma (mRCC) has been completely changed by the advent of agents targeting the vascular endothelial growth factor receptor and mammalian target of rapamycin (mTOR) pathway. The employment of mTOR inhibitors everolimus and temsirolimus has been reported to improve the outcome of patients with mRCC in different settings. Unfortunately, several mechanisms have been shown to be implicated in the development of resistance to mTOR inhibitors. Here we describe the role of the mTOR pathway in RCC development and metastasization. Furthermore, we discuss the role of the mTOR pathway as a therapeutic target in this context and the mechanisms associated with the development of drug resistance.
Santoni M., Massari F. (2016). mTOR Pathway in Renal Cell Carcinoma, 1, 417-428 [10.1016/B978-0-12-802733-2.00026-8].
mTOR Pathway in Renal Cell Carcinoma
Massari F.Secondo
2016
Abstract
The therapeutic approach of patients with metastatic renal cell carcinoma (mRCC) has been completely changed by the advent of agents targeting the vascular endothelial growth factor receptor and mammalian target of rapamycin (mTOR) pathway. The employment of mTOR inhibitors everolimus and temsirolimus has been reported to improve the outcome of patients with mRCC in different settings. Unfortunately, several mechanisms have been shown to be implicated in the development of resistance to mTOR inhibitors. Here we describe the role of the mTOR pathway in RCC development and metastasization. Furthermore, we discuss the role of the mTOR pathway as a therapeutic target in this context and the mechanisms associated with the development of drug resistance.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
